Lifespan Rhode Island Hospital

Providence, RI

Sorting 3 by

Accepting patients

SUCCESSOR-2

Phase 3 Study Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  • CELMoD
  • Randomization
  • Phase 3

Not yet accepting

DREAMM-10

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 3

Accepting patients

IDP-023

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
  • Natural Killer Cells (Allogeneic)
  • Phase 1/2